Carmustine wafer implantation for high-grade gliomas: Evidence-based safety efficacy and practical recommendations from the Neuro-oncology Club of the French Society of Neurosurgery.
暂无分享,去创建一个
A Roux | F. Caire | P. Metellus | J. Pallud | P. Menei | J Pallud | P Menei | A. Roux | J. Guyotat | F Caire | P Metellus | J Guyotat
[1] Mitchel S Berger,et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article. , 2012, Journal of neurosurgery.
[2] G. Maira,et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent glioblastoma , 2012, Acta Neurochirurgica.
[3] H. Duffau,et al. Surgical resection of incidental diffuse gliomas involving eloquent brain areas. Rationale, functional, epileptological and oncological outcomes. , 2017, Neuro-Chirurgie.
[4] J. Villemure,et al. Excretion of a radiolabelled anticancer biodegradable polymeric implant from the rabbit brain. , 1995, Biomaterials.
[5] P. Menei,et al. Traitement chirurgical des glioblastomes , 2010 .
[6] G. Gallia,et al. MGMT inactivation and clinical response in newly diagnosed GBM patients treated with Gliadel , 2015, Journal of Clinical Neuroscience.
[7] R. Mirimanoff,et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. , 2009, The Lancet. Oncology.
[8] M. Sabel,et al. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. , 2008, Current medical research and opinion.
[9] J. Tamada,et al. In vivo versus in vitro degradation of controlled release polymers for intracranial surgical therapy. , 1994, Journal of biomedical materials research.
[10] T. Ryken,et al. Survival outcomes and safety of carmustine wafers in the treatment of high-grade gliomas: a meta-analysis , 2015, Journal of Neuro-Oncology.
[11] B. Devaux,et al. Long-term results of carmustine wafer implantation for newly diagnosed glioblastomas: a controlled propensity-matched analysis of a French multicenter cohort. , 2015, Neuro-oncology.
[12] W. Mason,et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant glioma: RESCUE study. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Berger,et al. Reoperation for recurrent high-grade glioma: a current perspective of the literature. , 2014, Neurosurgery.
[14] Mitchel S Berger,et al. An extent of resection threshold for newly diagnosed glioblastomas. , 2011, Journal of neurosurgery.
[15] T. Cloughesy,et al. Bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[16] O. Chinot,et al. Prognostic impact of O6‐methylguanine‐DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation , 2009, Cancer.
[17] C. Oppenheim,et al. Perioperative functional neuroimaging of gliomas in eloquent brain areas. , 2017, Neuro-Chirurgie.
[18] John Sampson,et al. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] C. Bettegowda,et al. Risk of surgical site infection in 401 consecutive patients with glioblastoma with and without carmustine wafer implantation , 2015, Neurological research.
[20] Yi-Hua Zhang,et al. Efficacy and safety of carmustine wafers in the treatment of glioblastoma multiforme: a systematic review. , 2014, Turkish neurosurgery.
[21] F. Giangaspero,et al. Phase II study of short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. , 2012, International journal of radiation oncology, biology, physics.
[22] Manfred Westphal,et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. , 2003, Neuro-oncology.
[23] R. Komotar,et al. The role of Gliadel wafers in the treatment of high-grade gliomas , 2013, Expert review of anticancer therapy.
[24] K. Stein,et al. Chemotherapeutic wafers for High Grade Glioma. , 2008, The Cochrane database of systematic reviews.
[25] P. Paquis,et al. [Second surgery for glioblastoma. A 4-year retrospective study conducted in both the Montpellier and Nice Departments of Neurosurgery. A literature review]. , 2010, Neuro-Chirurgie.
[26] H. Brem,et al. Morphological Characterization of Polyanhydride Biodegradable Implant Gliadel® During in Vitro and in Vivo Erosion Using Scanning Electron Microscopy , 1996, Pharmaceutical Research.
[27] M. Hingorani,et al. The sequential use of carmustine wafers (Gliadel®) and post-operative radiotherapy with concomitant temozolomide followed by adjuvant temozolomide: a clinical review , 2011, British journal of neurosurgery.
[28] E. Shaw,et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] Roland Schott,et al. Retrospective comparison of chemoradiotherapy followed by adjuvant chemotherapy, with or without prior gliadel implantation (carmustine) after initial surgery in patients with newly diagnosed high-grade gliomas. , 2012, International journal of radiation oncology, biology, physics.
[30] H. Mehdorn,et al. Growth pattern of tumor recurrence following bis-chloroethylnitrosourea (BCNU) wafer implantation in malignant glioma , 2013, Journal of Clinical Neuroscience.
[31] E. Bruera,et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] D. Osoba,et al. Short‐Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma , 2017, The New England journal of medicine.
[33] E. Mandonnet,et al. Technical principles of direct bipolar electrostimulation for cortical and subcortical mapping in awake craniotomy. , 2017, Neuro-Chirurgie.
[34] Y. Fujiyama,et al. Combination Chemotherapy Using Carboplatin (JM-8) and Etoposide (JET Therapy) for Recurrent Malignant Gliomas: A Phase II Study , 2002, Acta Neurochirurgica.
[35] V. Rohde,et al. First-line treatment of malignant glioma with carmustine implants followed by concomitant radiochemotherapy: a multicenter experience , 2010, Neurosurgical Review.
[36] Martin J. van den Bent,et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. , 2005, The New England journal of medicine.
[37] J. Uhm. Temozolomide in Elderly Patients With Newly Diagnosed Glioblastoma and Poor Performance Status: An ANOCEF Phase II Trial , 2012 .
[38] O. Pradier,et al. Impact of the per-operatory application of GLIADEL wafers (BCNU, carmustine) in combination with temozolomide and radiotherapy in patients with glioblastoma multiforme: Efficacy and toxicity , 2012, Clinical Neurology and Neurosurgery.
[39] M. McGirt,et al. The efficacy of carmustine wafers for older patients with glioblastoma multiforme: prolonging survival , 2011, Neurological research.
[40] D. Bigner,et al. Overall survival of newly diagnosed glioblastoma patients receiving carmustine wafers followed by radiation and concurrent temozolomide plus rotational multiagent chemotherapy , 2009, Cancer.
[41] Luc Taillandier,et al. Radiotherapy for glioblastoma in the elderly. , 2007, The New England journal of medicine.
[42] H. Steiger,et al. Evaluation of post-operative complications associated with repeat resection and BCNU wafer implantation in recurrent glioblastoma , 2014, Acta Neurochirurgica.
[43] F. Yamasaki,et al. A Multicenter Phase I/II Study of the BCNU Implant (Gliadel ® Wafer) for Japanese Patients with Malignant Gliomas , 2013, Neurologia medico-chirurgica.
[44] L. Crinò,et al. Phase II trial of carboplatin and etoposide for patients with recurrent high-grade glioma , 2004, British Journal of Cancer.
[45] J. Barr,et al. The effects of the NICE Technology Appraisal 121 (Gliadel and Temozolomide) on survival in high-grade glioma , 2012, British journal of neurosurgery.
[46] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas , 1995, The Lancet.
[47] P. Peruzzi,et al. Implanted Carmustine Wafers Followed by Concomitant Radiochemotherapy to Treat Newly Diagnosed Malignant Gliomas: Prospective, Observational, Multicenter Study on 92 Cases , 2013, Annals of Surgical Oncology.
[48] T. Mikkelsen,et al. Salvage reirradiation for recurrent glioblastoma with radiosurgery: radiographic response and improved survival , 2008, Journal of Neuro-Oncology.
[49] Darell D. Bigner,et al. Phase II Trial of Bevacizumab and Irinotecan in Recurrent Malignant Glioma , 2007, Clinical Cancer Research.
[50] H Kalimo,et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. , 1997, Neurosurgery.
[51] K. Aldape,et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. , 2014, The New England journal of medicine.
[52] Guillermo Carbayo-Lozano,et al. Prognostic factors and survival in a prospective cohort of patients with high-grade glioma treated with carmustine wafers or temozolomide on an intention-to-treat basis , 2012, Acta Neurochirurgica.
[53] R. Tamargo,et al. The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. , 1992, Journal of neurosurgery.
[54] Elie A Akl,et al. [A reporting tool for practice guidelines in health care: the RIGHT statement]. , 2017, Zeitschrift fur Evidenz, Fortbildung und Qualitat im Gesundheitswesen.
[55] Dima Suki,et al. Extent of resection of glioblastoma revisited: personalized survival modeling facilitates more accurate survival prediction and supports a maximum-safe-resection approach to surgery. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[56] H. Duffau,et al. Intérêt d’une seconde chirurgie d’exérèse dans les glioblastomes. Étude rétrospective sur quatre ans aux centres hospitalo-universitaires de Montpellier et de Nice et revue de la littérature , 2010 .
[57] Z L Gokaslan,et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. , 2001, Journal of neurosurgery.
[58] D. Kondziolka,et al. Morbidity and survival after 1,3-bis(2-chloroethyl)-1-nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. , 1999, Neurosurgery.
[59] H. Maximilian Mehdorn,et al. Localized BCNU chemotherapy and the multimodal management of malignant glioma , 2009 .
[60] W. Saltzman,et al. Pharmacokinetics of the Carmustine Implant , 2002, Clinical pharmacokinetics.
[61] W. Mason,et al. Canadian recommendations for the treatment of recurrent or progressive glioblastoma multiforme. , 2011, Current oncology.
[62] Kenneth Hess,et al. The influence of maximum safe resection of glioblastoma on survival in 1229 patients: Can we do better than gross-total resection? , 2016, Journal of neurosurgery.
[63] M. Bernaudin,et al. O-Methylguanine-DNA Methyltransferase (MGMT) Promoter Methylation and Low MGMT-Encoded Protein Expression as Prognostic Markers in Glioblastoma Patients Treated With Biodegradable Carmustine Wafer Implants After Initial Surgery Followed by Radiotherapy With Concomitant and Adjuvant Temozolomide , 2012 .
[64] A. Silvani,et al. Prospective study of carmustine wafers in combination with 6-month metronomic temozolomide and radiation therapy in newly diagnosed glioblastoma: preliminary results. , 2013, Journal of neurosurgery.
[65] G. Reifenberger,et al. MGMT promoter methylation status and prognosis of patients with primary or recurrent glioblastoma treated with carmustine wafers , 2013, British journal of neurosurgery.
[66] J. Debus,et al. Efficacy of fractionated stereotactic reirradiation in recurrent gliomas: long-term results in 172 patients treated in a single institution. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[67] R. Labianca,et al. Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO) , 2009, Cancer Chemotherapy and Pharmacology.
[68] L. Capelle,et al. Biodegradable Carmustine Wafers (Gliadel) Alone or in Combination with Chemoradiotherapy: The French Experience , 2010, Annals of Surgical Oncology.
[69] Winand N M Dinjens,et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[70] C. Delmaire,et al. Intraoperative MRI for the management of brain lesions adjacent to eloquent areas. , 2017, Neuro-Chirurgie.
[71] B. Devaux,et al. Extent of resection and Carmustine wafer implantation safely improve survival in patients with a newly diagnosed glioblastoma: a single center experience of the current practice , 2017, Journal of Neuro-Oncology.
[72] A. Abbruzzese,et al. A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma , 2010, Journal of neuro-oncology.
[73] B. Devaux,et al. Combining intraoperative carmustine wafers and Stupp regimen in multimodal first-line treatment of primary glioblastomas , 2015, British journal of neurosurgery.
[74] X. Armoiry,et al. Is fluorescence-guided surgery with 5-ala in eloquent areas for malignant gliomas a reasonable and useful technique? , 2017, Neuro-Chirurgie.
[75] G. Reifenberger,et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. , 2012, The Lancet. Oncology.
[76] G. Gallia,et al. Multiple resections for patients with glioblastoma: prolonging survival. , 2013, Journal of neurosurgery.
[77] M. McGirt,et al. Use of Gliadel (BCNU) Wafer in the Surgical Treatment of Malignant Glioma: A 10-Year Institutional Experience , 2008, Annals of Surgical Oncology.
[78] Kris A Smith,et al. Gliadel wafer implantation combined with standard radiotherapy and concurrent followed by adjuvant temozolomide for treatment of newly diagnosed high-grade glioma: a systematic literature review , 2016, World Journal of Surgical Oncology.
[79] K. Stein,et al. Chemotherapy wafers for high grade glioma. , 2011, The Cochrane database of systematic reviews.
[80] S. Piantadosi,et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. , 1995, Lancet.
[81] L. Capelle,et al. Preoperative and intraoperative neurophysiological investigations for surgical resections in functional areas. , 2017, Neuro-Chirurgie.
[82] Z. Ram,et al. Gliadel® wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial , 2006, Acta Neurochirurgica.